4 display the 4-oxazolidinone core or the guanidine group of the synoxazolidinones but instead they contain quaternary ammonium groups implying potential acetylcholinesterase (AChE) inhibiting properties. AChE inhibitors are a class of drugs used for the treatment of Alzheimer's disease, glaucoma, myasthenia gravis (an autoimmune disorder) and the recovery of neuromuscular block after surgery. 10, 11 Some well-known AChE-inhibitors in clinical use today include physostigmine (6), a naturally occurring carbamate from the Calabar bean, used for the treatment of glaucoma. 10, 12 Examples of other current AChE-inhibitor based drugs are galanthamine (7) and donepezil, both used in most countries for the treatment of Alzheimer's disease. Several toxins such as nerve agents, insecticides and antiparasitic chemicals used in agriculture and aquaculture also act by inhibiting AChE and consist mostly of organophosphorus compounds and carbamates. 13, 14 At least three other marine natural products with similar structures to 1 and 2 have been reported in the literature. Compound 8, with significant structural similarities to 1 was isolated by Fattorusso et al. from the Caribbean sponge Pseudoceratina crassa (later reclassified as Aiolochroia crassa) in 1994. 15 Compound 8 was recently studied by
Munoz and co-workers and shown to display weak antiparasitic properties. 16 Compound 9 was isolated from another Caribbean sponge Verongula sp. but no biological activity was reported for the compound. 17 A derivative of 9, compound 10, was isolated from the sponge Verongia fistularis. 18 
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The current paper describes the isolation, structural characterisation and syntheses of 1 and 2 and the evaluation of their biological acitivities including AChE inhibition employing electric eel AChE.
RESULTS AND DISCUSSION
Step-wise fractionation of an aqueous extract of S. pulmonaria resulted in the isolation of two An initial inspection of the 2D NMR data revealed similar motifs in the aromatic region as those found in the synoxazolidinones. 7 The carbon shifts (Table 1) placed it adjacent to the ester oxygen. The gHMBC correlation from protons H-9/9'/9'' to C-8 supported the terminal trimethylated quaternary ammonium. The shift values of C-9/9'/9'' (δC 53.3) and H-9/9'/9'' (δH 3.14) are consistent with literature values. [19] [20] [21] The assignment of the terminal trimethylated ammonium was also supported by a loss of 59 mass units from the parent ion as indicated by a prominent peak at m/z 334 in the mass spectrum of 1.
Compound 2 displayed signals in the aromatic area of the 1 H and 13 C NMR spectra that were nearly identical to 1, suggesting a similar sub-structure. The chemical shift of H-4/4' is somewhat lower than that of the corresponding protons found in both 1 and the synoxazolidinones due to the methylene at C-6. The H-6 methylene protons displayed a high shift (δH 3.38) and showed gHMBC correlations to C-4/4', C-5 and the amide carbonyl C-7
placing it between the amide and the aromatic ring. The chemical shifts for H-6, C-6 and C-7 correlated well with a similar synthetic methoxy phenyl acetamide derivative of orthidine F. Because the purification led to sample loss, and the incomplete NMR data of the compounds, total synthesis was required to generate sufficient material for structural verification and biological testing. Compound 1 was prepared in one step. DCC was used as coupling agent to react 3,5-dibromo-4-methoxybenzoic acid and choline chloride in the presence of a catalytic amount of DMAP in CH2Cl2. The reaction was slow and sufficient amounts of 1 could only be obtained after an extended reaction time followed by HPLC purification. Several different solvent systems were evaluated, but only CH2Cl2 generated 1 due to solubility issues. Compound 2 was synthesised in three steps from 4-methoxyphenylacetic acid which was initially dibrominated with Br2/FeBr3 to produce 3,5-(dibromo-4-methoxyphenyl)acetic acid (2a)
according to Weller et al. 24 The bromination reaction was followed with MS and a complete 10 conversion to the desired dibrominated product required additional Br2/FeBr3 after 24 h.
Compound 2a was then coupled with 5-(dimethylamino)amylamine using HBTU as coupling
. N-methylation of 2b with CH3I completed the synthesis of 2. The synthetic routes to 1 and 2 are displayed in Scheme 1. (Table S3) . This is further supported by comparing the 2D-NMR data.
The para-methoxy dibrominated phenyl group moiety is a common structural motif among marine secondary metabolites, and particularly those that are tyrosine derivatives. 25 The isolated compounds bear structural resemblances with not only the synoxazolidinones, 7, 8 and 8, 9 and 10 15, 17, 18 but also with ianthelline, 26 and subereamine B 27 amongst others.
As both pulmonarins are terminally trimethylated ammonium compounds they were evaluated as AChE inhibitors in addition to the standard screens routinely performed during our screening process. 4 Electric eel AChE, sharing a high degree of sequence homology and having a 3D structure very similar to human AchE, 28 was employed as a model vertebrate AChE system and the well-established method of Ellman was employed to study the inhibition kinetics. g/mL (20 µM) for 2.
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A Ki of 9 g/mL (20 µM) for 2 indicates moderate binding affinities for vertebrate AChE, similar to that of the FDA-approved drug galanthamine. 32 The As an allosteric inhibitor of AChE, the presence of a quaternary nitrogen in both compounds suggests binding through electrostatic interactions at the peripheral anionic site (PAS) of the enzyme, which is located on the surface of the protein at the entrance of the active site cleft. This site is implicated in a number of non-classical functions such as amyloid deposition, cell adhesion and neurite outgrowth. 34 The PAS is thus a potential target in rational drug design for the development of novel and improved inhibitors and therapeutics for the treatment of neural cancers, nerve regeneration and neurodegenerative disorders such as Alzheimer's disease. 11, 34 QSAR studies of 1 and 2 could potentially contribute to future development of new drug candidates in various therapeutic fields.
14 We have previously reported that the 40/60 (v/v) CH3CN/H2O SPE fraction of S. pulmonaria exhibited antibacterial activity against a number of bacteria, showing an activity of 160 µg/ml against Corynebacterium glutamicum and 80 µg/ml against Staphylococcus aureus. 35 These compounds were therefore also included in the extensive screening performed at MabCent to investigate other potential bioactivities. 4 A lack of activity at concentrations above 100 µg/mL classified the compounds as "inactive" in all assays apart from the antibacterial screen.
Compound 1 displayed only very mild activity against one bacterial strain, C. glutamicum, at a concentration of 500 µg/mL indicating a possible synergistic effect in the active fraction.
Compound 2 was slightly more active against C. glutamicum displaying a minimal inhibitory concentration of 250 µg/mL. No activities were seen in the other bacterial screens in our panel (test strains used were S. aureus (ATTC 9144), E. coli (ATCC 25922), P. aeruginosa (ATTC 27853), and C. glutamicum (ATTC 13032)) (data not included). As well as testing negative against other bacteria, both 1 and 2 also tested negative for cytotoxic activities against three adherent cancer cell lines (A2058 melanoma, HT29 colon carcinoma and MCF7 breast carcinoma cells) and against adherent, non-malignant lung fibroblasts (MRC-5 cells) (data not included). They were also inactive in an anti-inflammatory assay targeted against TNF-α and in a biofilm formation inhibition assay using S. epidermidis (ATCC 35984) (data not included).
Finally 1 and 2 were shown to be inactive as cellular antioxidants (data not included).
Compounds 1 and 2 thus appear to possess a highly specific action as reversible non-competitive AChE inhibitors displaying no apparent cellular toxicity. As reported for the synoxazolidinones (3-5), it was not possible to determine whether symbiotic microorganisms are responsible for the biosynthesis of 1 and 2 which is a common case for marine natural products. 1 Based on the key structural differences between the synoxazolidinones and the compounds in the present study it seems unlikely that they share a common biosynthetic route in the organism apart from being tyrosine derivatives. Compound 1 can be considered as a dibrominated version of phydroxybenzoylcholine which has been isolated from the seeds of Sinapis albae and it was proposed to originate biosynthetically from a p-hydroxy benzyl alcohol derivative. 36, 37 An analogous biosynthetic route towards 1 is therefore plausible. The proposed biosynthesis of 2 is similar and is suggested to be derived from amide formation between methylated 2-(4-hydroxy-3,5-dibromophenyl)acetic acid and ascophylline, both previously described in extracts of marine organisms 38, 39 .
CONCLUSIONS
Two new marine bioactive compounds have been isolated and characterised from S. pulmonaria.
Curtailed by the lack of the natural compounds, total synthesis provided enough material for structure verification and biological testing. Both compounds turned out to be nontoxic, reversible, non-competitive inhibitors of AChE. The isolation of 1 and 2 yet again demonstrates the chemical diversity of the cold-water marine organism S. pulmonaria and the potential of the species for the discovery of new structural motifs for further lead compound development in a number of therapeutic areas.
EXPERIMENTAL SECTION

General Experimental Procedures
UV spectrum was determined on a Lambda 25 spectrometer from Perkin Elmer Instruments. 3,5-(dibromo-4-methoxyphenyl)acetic acid (2a)
2a was prepared in 21% yield according to the method described by Weller et al. 24 Spectral data matched those previously reported. 
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